Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com, Baral ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Sarepta Therapeutics slashed its share price by 44 percent last week following price target cuts from two investment companies.

Understanding Analyst Ratings: A Comprehensive Breakdown An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics.

In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent downside.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the Massive Sell-Offs: These 10 Stocks Shockingly Nosedived. Sarepta Therapeutics slashed its share price by 44 percent last week following price ...

Shares of Sarepta traded over 7% lower on Wednesday afternoon. Sarepta announced the death of a second patient following treatment with Elevidys earlier this month.

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Trimble is now the #23 analyst pick, moving up by 1 spot. This rank is ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation ...

FDA evaluating further regulatory actions after deaths Elevidys is the only gene therapy for Duchenne muscular dystrophy Sarepta suggested updating Elevidys' label June 24 (Reuters) - The U.S ...

A high-level overview of Sarepta Therapeutics, Inc. (SRPT) stock. View (SRPT) real-time stock price, chart, news, analysis, analyst reviews and more.